Best of Oncology Podcast Series: Recent Episodes
OncologyEducation
Welcome to the Best of Oncology podcast series, brought to you by OncologyEducation. Join our medical oncology experts as they discuss clinical implications of the latest advances and the hottest topics in the treatment and management of cancer.
Featuring Dr. Dr. Marcus Butler, Dr. Michael Smylie, and Dr. Jason Luke
Trials Discussed:
- Metastatic/Advanced Melanoma: COMBI-i Trial, LEAP-004 and SECOMBIT
- Adjuvant Trials in Melanoma: KEYNOTE 054 and CheckMate 238
- Metastatic/Advanced Melanoma: Local Therapy in Solitary Melanoma, NIVO+IPI vs NIVO and ILLUMINATE-204
- Non-Melanoma Skin Cancer: PD1 Blockage in Kaposi Sarcoma
This podcast has been made available through sponsorship from BMS.
Featuring Dr. Barbara Melosky, Dr. Parneet Cheema, and Dr. Peter Ellis.
Trials Discussed:
- Presidential Symposiums:CROWN, ADAURA, and Lung Art
- Metastatic NSCLC:ZENITH20 and TAK-788
- Metastatic NSCLC & EGFR Drug Conjugates: Amivantamab & Lazertinib and Patritumab Deruxtecan
- Stage III NSCLC:4-year survival of PACIFIC trial
- Neoadjuvant Trials:durvalumab in NSCLC and PRINCEPS trial
This podcast has been made available through sponsorship from Amgen.
Featuring Dr. Srikala Sridhar, Dr. Sebastien Hotte, and Dr. Petros Grivas
Trials Discussed:
- Bladder Cancer: KEYNOTE-361, DANUBE and TROPHY-U-01 Cohort 1
- Kidney/Prostate Cancer: CheckMate-9ER and COSMIC
- Prostate Cancer: IPATential150, PROfound and STAMPEDE
This podcast has been made available through sponsorship from BMS and Ipsen.
Featuring Dr. Scott Berry, Dr. Sharlene Gill and Dr. Marc Peeters
Trials Discussed:
- Gastroesophageal Cancer: CheckMate 649, ATTRACTION-4, KEYNOTE-062, KEYNOTE-590, and CheckMate 577
- GI Colorectal:KEYNOTE-177 and PRODIGE 13
This podcast has been made available through sponsorship by Amgen and BMS.
Featuring Dr. Heather McArthur, Dr. Erika Hamilton and Dr. Fabrice André.
Trials Discussed:
- HR+ MBC:SOLAR-1 and nextMONARCH
- EARLY HR+ DISEASE:Monarch E and PALLAS
- TNBC: IMpassion130, IMpassion131, IMpassion031 and ASCENT
Featuring:
- Dr. Bruce Colwell (Chair)
- Dr. Rachel Goodwin
This podcast has been made available through unrestricted sponsorship support from Amgen.
Learning Objectives:
- Discuss the evidence that supports current mCRC treatment recommendations
- Discuss treatment attrition and how it may impact clinical practice
- Describe the challenges to implement evidence based medicine and ways to overcome them
This episode features Dr. Richard LeBlanc, Dr. Darrell White, and Dr. Julie Stakiw.
This program was made possible by unrestricted sponsorship support from Amgen.
Trials Discussed:
-
First-line for transplant-eligible myeloma: STaMINA & GMMG-HD6: 00:02:02
-
First-line for non-transplant-eligible (or transplant-deferred) myeloma: ENDURANCE, SWOG 1211 & TOURMALINE-MM4: 00:11:42
-
First-line for transplant and non-transplant eligible myeloma: GMMG-CONCEPT: 00:23:04
-
Relapsed refractory multiple myeloma: BOSTON, IKEMA & CC-92480: 00:29:17
-
CAR-T anti-BCMA: KarMMa, CARTITUDE-1 & EVOLVE: 00:44:10
-
TCE anti-BCMA: TECLISTAMAB Phase I & TCE 2+1 (CC-93269): 00:55:20
This episode features Dr. Michael Smylie, Dr. Marcus Butler, and Dr. Jason Luke.
This program was made possible by unrestricted sponsorship support from Merck.
Trials Discussed:
- Advanced Melanoma: LN-144: 00:01:03
- Adjuvant Melanoma: COMBI-AD & EORTC 1325-MG/KEYNOTE 054: 00:10:41
- Metastatic Melanoma: COMBO IMMUNOTHERAPY (NIVOLIMAB + IPILUMAB): 00:28:55
- Advanced Melanoma: KEYNOTE-006: 00:38:13
- Neoadjuvant Melanoma: PRADO (Follow up of OpACIN-neo): 00:47:47
- Advanced Melanoma: LOW-DOSE IPI + PEMBRO IN MEL 53: 00:54:40
This episode features Dr. Gwyn Bebb, Dr. Philippe Bedard and Dr. Daniel Renouf.
Trials Discussed:
- MSI-H Tumors: KEYNOTE-177 & Pembrolizumab Monotherapy in MSI-H Pts: 00:01:15
- NTRK Tumors: NTRK-FP Solid Tumors - Integrated Analysis & Larotrectinib in Pts with TRK Fusion: 00:13:39
- RET Fusion+ Solid Tumors: BLU-667 in RET Fusion+ Solid Tumors: 00:22:46
- KRAS G12C Mutations: CodeBreak 100 & Prevalence of KRASG12C Mutations Utilizing ctCDA: 00:29:49
- Her-2 Positive Tumors: DESTINY-CRC01: 00:39:20
This episode features Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Jeffrey Rothenstein.
This program was made possible by unrestricted sponsorship support from AstraZeneca.
Trials Discussed:
- Adjuvant NSCLC: CTONG 1104 & ADAURA: 00:01:11
- Metastatic NSCLC: NEJ026, CONCURRENT OSIMERTINIB/GEFITINIB, JNJ-61186372, OSIMERTINIB 160MG, Poziotinib in previously treated EGFR exon 20 NSCLC patients: 00:17:21
- Stage IV NSCLC, Target HER2: T-Dxd DESTINY-LUNG01, GEOMETRY, Sym015, METex14 SA and potential AR mechanisms: 00:26:25
- Immunotherapy Updates in NSCLC: CHECKMATE 227 3 YEAR, CHECKMATE 9LA, CCTG BR34: 00:42:35
- Extensive Stage SCLC: ECOG-ACRIN EA5161, KEYNOTE-604 & CASPIAN: 00:55:28
This episode features Dr. Scott Berry, Dr. Sharlene Gill, and Dr. Marc Peeters. This program was made possible by unrestricted sponsorship support from Merck.
Trials Discussed:
- Metastatic Colorectal Cancer: KEYNOTE-177 & PANDA: 00:01:16
- Adjuvant Colorectal Cancer: IDEA, CALGB/SWOG 80702 & JCOG0603: 00:13:32
- Rectal Cancer: RAPIDO, UNICANCER PRODIGE 23 & OPRA: 00:32:09
- Pancreatic Cancer: SWOG S1505 & ESPAC 5F: 00:45:08
- Metastatic Gastroesophageal: DESTINY-Gastric 00:46:24
- Periporative/Neoadjuvant Gastroesophageal: PETRARCA, NRG/RTOG 1010 & RAMSES/FLOT7: 00:53:31
This episode features Dr. Daniel Heng, Dr. Srikala Sridhar and Dr. Kim Chi.
This program was made possible by unrestricted sponsorship support from Ipsen and Merck.
Trials Discussed:
- Bladder Cancer: JAVELIN & IMvigor010: 00:01:22
- Kidney Cancer: KEYNOTE-426 & OMNIVORE: 00:16:45
- Prostate Cancer: CONDOR & TheraP: 00:38:48
- Prostate Cancer: HERO, SPARTAN, PROSPER & ARAMIS: 00:54:39
This episode features Dr. Heather McArthur, Dr. Christine Brezden-Masley, and Dr. Christine Simmons.
This program was made possible by unrestricted sponsorship support from Mylan.
Trials Discussed:
- De Novo Stage IV Breast Cancer: ECOG-ACRIN (E2108) : 00:01:00
- HER2+ Breast Cancer, Adjuvant: KATHERINE & KAITLIN: 00:13:18
- HER2+ Breast Cancer, Neoadjuvant: TRAIN-2: 00:24:47
- Metastatic HER2+ Breast Cancer: HER2CLIMB: 00:35:52
- Metastatic Triple Negative Breast Cancer: KEYNOTE-355: 01:18:49
- Metastatic Triple Negative Breast Cancer: S1416: 01:30:12
Oncologists Dr. Andrew Robinson and Dr. Joshua Bauml, in conversation at the 2019 Eastern Canadian Oncology Opinion Series, discuss their experience with the changing landscapes in cancer care.
In this episode, we'll listen to Dr. Daniel Renouf, Dr. Jose Monzon and Dr. Jonathan Loree discuss precision medicine at ESMO 2019.
00:01 Introduction of the Best of Oncology Podcast
00:27 Introduction of Dr. Daniel Renouf, Dr. Jose Monzon and Dr. Jonathan Loree
01:22 Phase I Study of AMG 510
10:37 Abstract 528PD: Correlative analysis of CCTG CO.26
18:33 Abstract LBA30_PR: Correlative analysis of IDEA-FRANCE phase III trial
25:11 Abstract: LBA15_PR
33:20 TRK Fusion Updates
43:27 Discussion: The Future of Precision Medicine
In this episode, we'll listen to Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Peter Ellis discuss the important trials presented at ESMO 2019.
00:01 Introduction of the Best of Oncology Podcast
00:22 Introduction of Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Peter Ellis
01:33 LBA5 FLAURA OS
13:47 IMpower110 Study
19:06 LBA4 Checkmate 227
28:13 Small cell lung cancer - IMpower133, CASPIAN PD-L1
In this episode, we'll listen to Dr. Kala Sridhar, Dr. Sebastien Hotte and Dr. Petras Grivas discuss the important trials presented at ESMO 2019.
00:01 Introduction of the Best of Oncology Podcast
00:29 Introduction of Dr. Kala Sridhar, Dr. Sebastien Hotte and Dr. Petras Grivas
01:30 Bladder/Urothelial Cancer - EV-103 Trial, TROPHY-U-01 STUDY, IMvigor130, BISCAY Trial, NABUCCO Trial
27:38 Prostate Cancer - Phase III SPARTAN Study, STAMPEDE, PROfound Trial, CARD Trial, CCTG IND 232 Trial
52:37 Renal cell carcinoma - ENTRATA Trial
In this episode, we'll listen to Dr. Scott Berry, Dr. Sharlene Gill and Dr. Florian Lordick discuss the important trials presented at ESMO 2019.
00:01 Introduction of the Best of Oncology Podcast
00:30 Introduction of Dr. Scott Berry, Dr. Sharlene Gill and Dr. Florian Lordick
01:19 BEACON Trial
08:52 Circulating Tumour DNA Trial - IDEA Trial and 522O
20:08 ATTRACTION-3 Study
27:30 ANGEL study
32:35 KEYNOTE-062
36:12 CheckMate 459 Trial
42:27 ClarIDHy Trial
In this episode, we'll listen to Dr. Heather McArthur, Dr. Hope Rugo and Dr. Veronique Dieras discuss the important trials presented at ESMO 2019.
00:01 Introduction of the Best of Oncology Podcast
00:26 Introduction of Dr. Heather McArthur, Dr. Hope Rugo and Dr. Veronique Dieras
01:12 KEYNOTE-522
15:05 Targeted therapy and Immunotherapy in Breast Cancer
33:00 HER 2 + Metastatic Breast Cancer Updates
41:49 Hormone Receptor Positive Breast Cancer Updates
In this episode, we'll listen to Dr. Srikala Sridhar, Dr. Scott North and Dr. Alicia Morgans discuss the important trials presented at ASCO 2019.
01:01 - ENZAMET Study
12:49 - TITAN Study
19:00 - KEYNOTE-426 Study
28:25 - CALGB 90601 (Alliance)
38:29 - HCRN:GU14-182
In this episode, we'll listen to Dr. Sunil Verma, Dr. Hope Rugo and Dr. Peter Schmid discuss the important trials presented at ASCO 2019.
01:01 - Her 2 Positive Breast Cancer
18:59 - Hormone Receptor Positive
37:37 - Triple Negative Breast Cancer and Immunotherapy
In this episode, we'll listen to Dr. Barb Melosky, Dr. Sanjay Popat and Dr. Parneet Cheema discuss the important trials presented at ASCO 2019.
01:06 - Relay Trial
07:23 - GEFITNIB Phase III Trial
14:40 - TAK-788
20:00 - Geometry and TEPOTINIB Study
26:48 - Adjuvant Therapy
In this episode, we'll listen to Dr. Scott Berry, Dr. Marc Peeters and Dr. Sharlene Gill, discuss the important trials presented at ASCO 2019.
08:20 - Apact Trial
16:35 - Phase 3 Trial of 1st Line Chemo vs Pembrolizumab vs Chemo + Pembrolizumab for Metastatic Gastric CA
24:15 - Phase 3 Trial of 2nd Line Pembrolizumab vs Placebo for HCC
30:26 - ABC-06
35:35 - IDEA Study (High Risk Stage 2 Patients)
46:19 - Foxtrot Trial
In this episode, we'll listen to Dr. Gwyn Bebb, Dr. Daniel Renouf and Dr. Sebastien Hotte discuss the important trials presented at ASCO 2019.
01:11 - Broad Indications for Small Molecular Inhibitors, and DNA repair deficiency
26:56 - Broad Indications for Immunotherapy
In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best of San Antonio Breast Cancer Symposium in Toronto, where they shared their thoughts on the most impactful data released in Triple NegativeBreast Cancer at the flagship meeting a few weeks earlier.
In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best of San Antonio Breast Cancer Symposium in Toronto, where they shared their thoughts on the most impactful data released in HER2 Positive Breast Cancer at the flagship meeting a few weeks earlier.
In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best of San Antonio Breast Cancer Symposium in Toronto, where they shared their thoughts on the most impactful data released in Hormone Receptor Positive Breast Cancer at the flagship meeting a few weeks earlier.